AntiTIGIT

Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy Continued clinical benefit observed with the combination…

Les données issues d'études précliniques menées en collaboration avec le Fred Hutchinson Cancer Research Center seront présentées à l'ASH et apporteront une solide justification à…

Data from preclinical studies in collaboration with Fred Hutchinson Cancer Research Center will be presented at ASH and provide strong rationale for use of EOS-448 as a single agent and in…